For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 383,724 | 1,398,732* | 504,387 | 617,835 |
| General and administrative | - | - | - | 1,154,896 |
| Selling, general and administrative (including related party amounts of 190,583 and 0, respectively) | 1,542,658 | 1,074,763* | 1,256,284 | - |
| Total operating expenses | 1,926,382 | 2,473,495 | 1,760,671 | 1,772,731 |
| Loss from operations | -1,926,382 | -2,473,495* | -1,760,671 | -1,772,731 |
| Interest income | 78,676 | 4,561* | 68,682 | 71,638 |
| Net loss | -1,847,706 | -2,468,934 | -1,691,989 | -1,701,093 |
| Basic EPS | -0.48 | -3.403 | -1.65 | -1.66 |
| Diluted EPS | -0.48 | -3.403 | -1.65 | -1.66 |
| Basic Average Shares | 3,858,921 | 725,613 | 1,026,457 | 1,026,506 |
| Diluted Average Shares | 3,858,921 | 725,613 | 1,026,457 | 1,026,506 |
Dermata Therapeutics, Inc. (DRMA)
Dermata Therapeutics, Inc. (DRMA)